Pharmaceuticals

Hepion Pharmaceuticals

Hepion Pharmaceuticals released FY2026 Q1 earnings on May 14 (EST), actual revenue USD 0, actual EPS USD -0.0699

Hepion Pharmaceuticals released FY2025 Q4 earnings on March 12 (EST), actual revenue USD 0, actual EPS USD -0.0562

Hepion Pharmaceuticals released FY2025 earnings on March 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.8797 (forecast USD -260)

Hepion Pharmaceuticals released FY2025 9 Months Earnings on November 12 (EST), with actual revenue of USD 0 and EPS of USD -2.2851

Hepion Pharmaceuticals released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 0, actual EPS USD -0.0406

Hepion Pharmaceuticals released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -1.0016

Hepion Pharmaceuticals released FY2025 Q2 earnings on August 14 (EST) with actual revenue of USD 0 and EPS of USD -0.092

Hepion Pharmaceuticals Annual General Meeting Elects Directors

Hepion Pharmaceuticals released FY2025 Q1 earnings on May 19, 2025 (EST) with actual revenue of USD 0 and EPS of USD -2.1524

Hepion Pharmaceuticals Delays Release of 2025 First Quarter Financial Report

Hepion Pharmaceuticals Developing Therapies for NASH and Other Chronic Liver Diseases

Hepion Pharmaceuticals Signs LOI to Commercialize Diagnostic Tests

Hepion Pharmaceuticals and New Day Diagnostics Enter into Diagnostic Testing License Agreement

Hepion Pharmaceuticals released FY2024 Q4 earnings on April 8 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -11.1051 (forecast USD -98.5)

Hepion Pharmaceuticals released FY2024 annual earnings on April 8 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -107.3479 (forecast USD -571.5)

Hepion Pharmaceuticals released FY2024 9 Months Earnings on November 14 (EST), with actual revenue of 0 USD and EPS of -98.1837 USD

Hepion Pharmaceuticals released FY2024 Q3 earnings on November 14 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -36.2106 USD (forecast -95 USD)

Hepion Pharmaceuticals released FY2024 Q2 earnings on August 13 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -33.8429 USD (forecast -185.5 USD)

Hepion Pharmaceuticals released FY2024 Semi-Annual Earnings on August 13 (EST), with actual revenue of 0 USD and EPS of -62.3484 USD

Hepion Pharmaceuticals Reaches Merger Agreement with Pharma Two B

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

HEPA

Earnings Watch

Hepion Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0

LABU

Vincent LoPriore has disclosed a 21.46% stake in Hepion Pharmaceuticals, Inc., filed on May 1, 2026. This stake includes shares from Gravitas Capital LP and the Invictus Capital Advisors Pension Plan, both controlled by LoPriore. He intends to hold these shares for investment purposes and may acquire more in the future, but has no current plans for control changes or board alterations. LoPriore is the Executive Chairman of Hepion and has voting authority over the shares.

TradingView

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

iShares Global Healthcare

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Vincent LoPriore Discloses Investment at Hepion Pharmaceuticals with 21.46% Stake

SBIO

Hepion Pharmaceuticals has raised $700,000 through a private placement of 17.5 million shares at $0.04 each. The transaction, which closed on April 21, 2026, was conducted under Regulation D, Section 4(a)(2) and Rule 506(b). The shares are unregistered and subject to resale restrictions under U.S. securities laws. This move aims to strengthen the company's liquidity through equity financing.

Health Care Select Sector SPDR

iShares US Pharma

Invesco Biotechnology & Genome ETF

VG Health

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Hepion Pharmaceuticals Raises $700,000 in Private Placement of 17.5M Shares at $0.04

HELP

Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions | HELP Stock News

StockTitan

Cybin

Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions | HELP Stock News

Hepion Pharmaceuticals reported no revenue for 2025, with a net loss of $(8.28) million or $(0.88) per share, despite narrowing its operating loss to $(4.16) million from $(19.35) million in 2024. The company is shifting focus to CE-marked diagnostics for commercialization in non-U.S. markets after winding down its ASCEND-NASH trial due to funding issues. Cost reductions in R&D and administrative expenses contributed to lower losses. The strategic pivot aims to enhance market readiness in the EU with new diagnostic products.

Direxion S&P Biotech Bear 3X

Hepion Pharmaceuticals 2025 10-K: $0 Revenue, $(0.88) EPS on $(8.28) M Net Loss

Hepion Pharmaceuticals | 10-K: FY2025 Revenue: USD 0

Hepion Pharmaceuticals(HEPA.US)

Hepion Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0

Vincent LoPriore Discloses Investment at Hepion Pharmaceuticals with 21.46% Stake

Hepion Pharmaceuticals Raises $700,000 in Private Placement of 17.5M Shares at $0.04

Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions | HELP Stock News

Hepion Pharmaceuticals 2025 10-K: $0 Revenue, $(0.88) EPS on $(8.28) M Net Loss

Hepion Pharmaceuticals | 10-K: FY2025 Revenue: USD 0